{"entity":{"id":"idea-acc-pharmacist-interaction-review-oral-anticancer","kind":"idea","name":"Pharmacist interaction check before every oral cancer-drug prescription","aka":[],"tldr":"Oral kinase inhibitors, CDK4/6 inhibitors and hormonal agents interact with proton pump inhibitors, anticoagulants, statins and antiarrhythmics, and are increasingly prescribed to older patients taking all of them. A mandatory oncology pharmacist review at initiation, dose change and refill, with a structured monitoring plan, would catch these interactions systematically.","summary":"Oral kinase inhibitors, CDK4/6 inhibitors, and hormonal agents have clinically significant interactions with proton pump inhibitors, anticoagulants, statins, and antiarrhythmics, and are increasingly prescribed to older multimorbid patients. Studies find potential interactions in a large proportion of such patients. A mandatory oncology pharmacist review at initiation and dose change, with a structured monitoring plan, would catch these systematically.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Older and multimorbid patients are excluded and undertreated): Mohile et al., Evaluation of geriatric assessment and management on toxic effects of cancer treatment (GAP70+, Lancet 2021)","url":"https://doi.org/10.1016/S0140-6736(21)01789-X"}],"tags":[],"related":["idea-acc-structured-deprescribing-at-diagnosis"],"cancers":[],"sections":[],"technologies":["kinase-inhibitors","cdk46-inhibitor"],"targets":[],"drugs":["palbociclib","osimertinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-aging-comorbidity","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"Mandatory pharmacist review will reduce clinically significant drug interactions at initiation by at least 70% and reduce interaction-related adverse events and dose interruptions.","rationale":"Pharmacist review is the established safeguard for intravenous chemotherapy; oral agents escaped it because they are dispensed like ordinary prescriptions.","test":"A before-and-after study across five centres with interaction rates, adverse events, and dose interruptions as endpoints.","maturity":"early-clinical","actor":"clinic","cost":"small","horizonYears":1},"route":"/ideas/idea-acc-pharmacist-interaction-review-oral-anticancer/","neighbours":{"idea":[{"id":"idea-acc-structured-deprescribing-at-diagnosis","kind":"idea","name":"Structured deprescribing review at cancer diagnosis and again at transition to palliative care","route":"/ideas/idea-acc-structured-deprescribing-at-diagnosis/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"}],"bottleneck":[{"id":"b-aging-comorbidity","kind":"bottleneck","name":"Older and multimorbid patients are excluded and undertreated","route":"/bottlenecks/b-aging-comorbidity/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}]}}